GB202108594D0 - Treatment or prevention of ischaemia reperfusion injury - Google Patents

Treatment or prevention of ischaemia reperfusion injury

Info

Publication number
GB202108594D0
GB202108594D0 GBGB2108594.9A GB202108594A GB202108594D0 GB 202108594 D0 GB202108594 D0 GB 202108594D0 GB 202108594 A GB202108594 A GB 202108594A GB 202108594 D0 GB202108594 D0 GB 202108594D0
Authority
GB
United Kingdom
Prior art keywords
prevention
treatment
reperfusion injury
ischaemia reperfusion
ischaemia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2108594.9A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cambridge Enterprise Ltd
Original Assignee
Cambridge Enterprise Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cambridge Enterprise Ltd filed Critical Cambridge Enterprise Ltd
Priority to GBGB2108594.9A priority Critical patent/GB202108594D0/en
Publication of GB202108594D0 publication Critical patent/GB202108594D0/en
Priority to JP2023577694A priority patent/JP2024522767A/ja
Priority to PCT/GB2022/051436 priority patent/WO2022263792A1/en
Priority to CA3222535A priority patent/CA3222535A1/en
Priority to EP22730594.3A priority patent/EP4355315A1/en
Priority to AU2022294208A priority patent/AU2022294208A1/en
Priority to US18/568,243 priority patent/US20240252457A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GBGB2108594.9A 2021-06-16 2021-06-16 Treatment or prevention of ischaemia reperfusion injury Ceased GB202108594D0 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
GBGB2108594.9A GB202108594D0 (en) 2021-06-16 2021-06-16 Treatment or prevention of ischaemia reperfusion injury
JP2023577694A JP2024522767A (ja) 2021-06-16 2022-06-08 虚血再灌流傷害の処置または予防
PCT/GB2022/051436 WO2022263792A1 (en) 2021-06-16 2022-06-08 Treatment or prevention of ischaemia reperfusion injury
CA3222535A CA3222535A1 (en) 2021-06-16 2022-06-08 Treatment or prevention of ischaemia reperfusion injury
EP22730594.3A EP4355315A1 (en) 2021-06-16 2022-06-08 Treatment or prevention of ischaemia reperfusion injury
AU2022294208A AU2022294208A1 (en) 2021-06-16 2022-06-08 Treatment or prevention of ischaemia reperfusion injury
US18/568,243 US20240252457A1 (en) 2021-06-16 2022-06-08 Treatment or Prevention of Ischaemia Reperfusion Injury

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2108594.9A GB202108594D0 (en) 2021-06-16 2021-06-16 Treatment or prevention of ischaemia reperfusion injury

Publications (1)

Publication Number Publication Date
GB202108594D0 true GB202108594D0 (en) 2021-07-28

Family

ID=76954409

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2108594.9A Ceased GB202108594D0 (en) 2021-06-16 2021-06-16 Treatment or prevention of ischaemia reperfusion injury

Country Status (7)

Country Link
US (1) US20240252457A1 (https=)
EP (1) EP4355315A1 (https=)
JP (1) JP2024522767A (https=)
AU (1) AU2022294208A1 (https=)
CA (1) CA3222535A1 (https=)
GB (1) GB202108594D0 (https=)
WO (1) WO2022263792A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201918022D0 (en) * 2019-12-09 2020-01-22 Cambridge Entpr Ltd Treatment or prevention of Ischaemic Stroke Reperfusion Injury
WO2025125766A1 (en) 2023-12-12 2025-06-19 Cambridge Enterprise Limited Treatment or prevention of ischaemia reperfusion injury

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016001686A1 (en) 2014-07-03 2016-01-07 Medical Research Council SUCCINATE DEHYDROGENASE INHIBITORS (SDHi's)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3416634A4 (en) * 2016-02-15 2019-10-09 Artyomov, Maxim IMMUNOMODULATORY AGENTS AND METHOD FOR USE THEREOF
GB201918022D0 (en) * 2019-12-09 2020-01-22 Cambridge Entpr Ltd Treatment or prevention of Ischaemic Stroke Reperfusion Injury

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016001686A1 (en) 2014-07-03 2016-01-07 Medical Research Council SUCCINATE DEHYDROGENASE INHIBITORS (SDHi's)

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
"Handbook for Pharmaceutical Additives", 2007, SYNAPSE INFORMATION RESOURCES, INC.
"Remington: The Science and Practice of Pharmacy", 2006, LIPPINCOTT, WILLIAMS AND WILKINS
ABUCHOWSKIDAVIS: "Soluble Polymer-Enzyme Adducts, Enzymes as Drugs", 1981, WILEY-INTERSCIENCE,, pages: 367 - 383
DAVIDSON SM ET AL.: "Multitarget Strategies to Reduce Myocardial Ischemia/Reperfusion Injury", JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY., vol. 73, 2019, pages 89 - 99
FEIGIN VL ET AL.: "Global and regional burden of stroke during 1990-2010: findings from the Global Burden of Disease Study 2010", LANCET, vol. 383, no. 9913, 2014, pages 245 - 254
KALOGERIS T ET AL.: "Cell biology of ischemia/reperfusion injury", INTERNATIONAL REVIEW OF CELL AND MOLECULAR BIOLOGY., vol. 298, 2012, pages 229 - 317
KLONER RA ET AL.: "New and revisited approaches to preserving the reperfused myocardium", NATURE REVIEWS CARDIOLOGY., vol. 14, 2017, pages 679 - 693
KULA-ALWAR D ET AL.: "Targeting Succinate Metabolism in Ischemia/Reperfusion Injury", CIRCULATION, vol. 140, no. 24, 10 December 2019 (2019-12-10), pages 1968 - 1970, XP055780869, DOI: 10.1161/CIRCULATIONAHA.119.042791
MARTIN JL ET AL.: "Succinate accumulation drives ischaemia-reperfusion injury during organ transplantation", NATURE METABOLISM., vol. 1, 2019, pages 966 - 974
MURPHY E ET AL.: "Mechanisms underlying acute protection from cardiac ischemia-reperfusion injury", PHYSIOLOGICAL REVIEWS, vol. 88, 2008, pages 581 - 609
PRAGHA ET AL., PRODRUGS OF MALONATE WITH ENHANCED INTRACELLULAR DELIVERY PROTECT AGAINST CARDIAC ISCHEMIA-REPERFUSION INJURY IN VIVO
VALLS-LACALLE L ET AL.: "Succinate dehydrogenase inhibition with malonate during reperfusion reduces infarct size by preventing mitochondrial permeability transition", CARDIOVASCULAR RESEARCH., vol. 109, 2016, pages 374 - 384, XP055617303, DOI: 10.1093/cvr/cvv279

Also Published As

Publication number Publication date
CA3222535A1 (en) 2022-12-22
JP2024522767A (ja) 2024-06-21
US20240252457A1 (en) 2024-08-01
WO2022263792A1 (en) 2022-12-22
EP4355315A1 (en) 2024-04-24
AU2022294208A1 (en) 2024-01-25

Similar Documents

Publication Publication Date Title
GB202006665D0 (en) Treatment of ischaemia
GB202108594D0 (en) Treatment or prevention of ischaemia reperfusion injury
GB202005097D0 (en) Treatment and/or prevention of covid-19 infection
PT3558335T (pt) Inibição da caspase-1 e sua utilização na prevenção e tratamento de doenças neurológicas
GB201802864D0 (en) Prevention or treatment of cardiac arrhytmia and sudden cardiac death
GB201918022D0 (en) Treatment or prevention of Ischaemic Stroke Reperfusion Injury
GB202108224D0 (en) Treatment
SMT202500404T1 (it) Trattamento combinato di compromissione del cervello
IL270306A (en) Prevention and treatment of pre-myeloid and myeloid malignancies
GB201615035D0 (en) Treatment and prevention of viral infection
GB202001353D0 (en) Treatment of skin conditions
GB202002711D0 (en) Treatment
GB202101251D0 (en) Treatment of conditions
GB202316026D0 (en) Methods of prevention or treatment
PL4313106T3 (pl) Leczenie dysfagii
GB202102247D0 (en) Treatment of brain injuries
GB202104753D0 (en) Treatment of ophthalmological conditions
GB202114129D0 (en) Treatment of traumatic brain injury
PL4225291T3 (pl) Leczenie cholangiopatii za pomocą seladelparu
GB202004938D0 (en) Treatment of Ophthalmological Conditions
GB202006727D0 (en) Treatment of traumatic brain injury
GB202110146D0 (en) Treatment of respiratory conditions
GB201913338D0 (en) Treatment of spinal cord injury
GB202118006D0 (en) Methods of treatment
GB202118007D0 (en) Methods of treatment

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)